173 related articles for article (PubMed ID: 35315502)
1. Combined inhibition of IL‑6 and IL‑8 pathways suppresses ovarian cancer cell viability and migration and tumor growth.
Zhang R; Roque DM; Reader J; Lin J
Int J Oncol; 2022 May; 60(5):. PubMed ID: 35315502
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of GP130/STAT3 and EMT by combined bazedoxifene and paclitaxel treatment in ovarian cancer.
Park SA; Kim LK; Park HM; Kim HJ; Heo TH
Oncol Rep; 2022 Mar; 47(3):. PubMed ID: 35029286
[TBL] [Abstract][Full Text] [Related]
3. IL6-induced metastasis modulators p-STAT3, MMP-2 and MMP-9 are targets of 3,3'-diindolylmethane in ovarian cancer cells.
Zou M; Zhang X; Xu C
Cell Oncol (Dordr); 2016 Feb; 39(1):47-57. PubMed ID: 26510945
[TBL] [Abstract][Full Text] [Related]
4. Blocking Interleukin-6 and Interleukin-8 Signaling Inhibits Cell Viability, Colony-forming Activity, and Cell Migration in Human Triple-negative Breast Cancer and Pancreatic Cancer Cells.
Fu S; Lin J
Anticancer Res; 2018 Nov; 38(11):6271-6279. PubMed ID: 30396947
[TBL] [Abstract][Full Text] [Related]
5. Synergistic Effect of Bazedoxifene and PARP Inhibitor in the Treatment of Ovarian Cancer Regardless of BRCA Mutation.
Zhang R; Wang T; Lin J
Anticancer Res; 2021 May; 41(5):2277-2286. PubMed ID: 33952453
[TBL] [Abstract][Full Text] [Related]
6. Bazedoxifene as a Novel GP130 Inhibitor for Pancreatic Cancer Therapy.
Wu X; Cao Y; Xiao H; Li C; Lin J
Mol Cancer Ther; 2016 Nov; 15(11):2609-2619. PubMed ID: 27535971
[TBL] [Abstract][Full Text] [Related]
7. Down-regulating IL-6/GP130 targets improved the anti-tumor effects of 5-fluorouracil in colon cancer.
Li S; Tian J; Zhang H; Zhou S; Wang X; Zhang L; Yang J; Zhang Z; Ji Z
Apoptosis; 2018 Jun; 23(5-6):356-374. PubMed ID: 29777330
[TBL] [Abstract][Full Text] [Related]
8. Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer.
Tian J; Chen X; Fu S; Zhang R; Pan L; Cao Y; Wu X; Xiao H; Lin HJ; Lo HW; Zhang Y; Lin J
Breast Cancer Res Treat; 2019 Jun; 175(3):553-566. PubMed ID: 30852762
[TBL] [Abstract][Full Text] [Related]
9. The CXCR2 antagonist, SCH-527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models.
Ning Y; Labonte MJ; Zhang W; Bohanes PO; Gerger A; Yang D; Benhaim L; Paez D; Rosenberg DO; Nagulapalli Venkata KC; Louie SG; Petasis NA; Ladner RD; Lenz HJ
Mol Cancer Ther; 2012 Jun; 11(6):1353-64. PubMed ID: 22391039
[TBL] [Abstract][Full Text] [Related]
10. Bazedoxifene as a novel GP130 inhibitor for Colon Cancer therapy.
Wei J; Ma L; Lai YH; Zhang R; Li H; Li C; Lin J
J Exp Clin Cancer Res; 2019 Feb; 38(1):63. PubMed ID: 30736824
[TBL] [Abstract][Full Text] [Related]
11. The effects of 17β-estradiol and a selective estrogen receptor modulator, bazedoxifene, on ovarian carcinogenesis.
Romero IL; Lee W; Mitra AK; Gordon IO; Zhao Y; Leonhardt P; Penicka CV; Mui KL; Krausz TN; Greene GL; Lengyel E
Gynecol Oncol; 2012 Jan; 124(1):134-41. PubMed ID: 21996264
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of interleukin 8/C‑X-C chemokine receptor 1,/2 signaling reduces malignant features in human pancreatic cancer cells.
Fu S; Chen X; Lin HJ; Lin J
Int J Oncol; 2018 Jul; 53(1):349-357. PubMed ID: 29749433
[TBL] [Abstract][Full Text] [Related]
13. CAFs enhance paclitaxel resistance by inducing EMT through the IL‑6/JAK2/STAT3 pathway.
Wang L; Zhang F; Cui JY; Chen L; Chen YT; Liu BW
Oncol Rep; 2018 May; 39(5):2081-2090. PubMed ID: 29565447
[TBL] [Abstract][Full Text] [Related]
14. A small molecule STAT3 inhibitor, LLL12, enhances cisplatin‑ and paclitaxel‑mediated inhibition of cell growth and migration in human ovarian cancer cells.
Zhang R; Chen X; Fu S; Xu L; Lin J
Oncol Rep; 2020 Sep; 44(3):1224-1232. PubMed ID: 32705214
[TBL] [Abstract][Full Text] [Related]
15. Repurposing the selective estrogen receptor modulator
Thilakasiri P; Huynh J; Poh AR; Tan CW; Nero TL; Tran K; Parslow AC; Afshar-Sterle S; Baloyan D; Hannan NJ; Buchert M; Scott AM; Griffin MD; Hollande F; Parker MW; Putoczki TL; Ernst M; Chand AL
EMBO Mol Med; 2019 Apr; 11(4):. PubMed ID: 30885958
[TBL] [Abstract][Full Text] [Related]
16. Combined bazedoxifene and paclitaxel treatments inhibit cell viability, cell migration, colony formation, and tumor growth and induce apoptosis in breast cancer.
Fu S; Chen X; Lo HW; Lin J
Cancer Lett; 2019 Apr; 448():11-19. PubMed ID: 30707920
[TBL] [Abstract][Full Text] [Related]
17. Leukemia inhibitory factor functions in parallel with interleukin-6 to promote ovarian cancer growth.
McLean K; Tan L; Bolland DE; Coffman LG; Peterson LF; Talpaz M; Neamati N; Buckanovich RJ
Oncogene; 2019 Feb; 38(9):1576-1584. PubMed ID: 30305729
[TBL] [Abstract][Full Text] [Related]
18. Inhibitor of signal transducer and activator of transcription 3 (STAT3) suppresses ovarian cancer growth, migration and invasion and enhances the effect of cisplatin in vitro.
Tang YJ; Sun ZL; Wu WG; Xing J; He YF; Xin DM; Han P
Genet Mol Res; 2015 Mar; 14(1):2450-60. PubMed ID: 25867391
[TBL] [Abstract][Full Text] [Related]
19. A small-molecule antagonist of CXCR1 and CXCR2 inhibits cell proliferation, migration and invasion in melanoma via PI3K/AKT pathway.
Shang FM; Li J
Med Clin (Barc); 2019 Jun; 152(11):425-430. PubMed ID: 30340844
[TBL] [Abstract][Full Text] [Related]
20. IL‑6 and IL‑8 enhance factor H binding to the cell membranes.
Popek S; Kapka-Skrzypczak L; Sawicki K; Wolińska E; Skrzypczak M; Czajka M
Mol Med Rep; 2016 May; 13(5):3886-94. PubMed ID: 27035765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
